AWM
NKTR icon

AE Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

AE Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,378
Closed -$369K – 1316
2020
Q1 		$369K Buy
+1,378
New +$426K 0.01% 798

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

AE Wealth Management's NKTR Position: Q2 2020 in Review

AE Wealth Management sold out of Nektar Therapeutics (NKTR) in Q2 2020, closing a stake of 1,378 shares — an estimated $369K sold.

AE Wealth Management first reported a position in NKTR in Q1 2020 and held it in 1 quarter. The position peaked at $369K in Q1 2020. 260 funds tracked by Wall St. Rank hold NKTR as of Q2 2020.

  • AE Wealth Management reported no remaining Nektar Therapeutics position as of Q2 2020 after selling out during the quarter.
  • AE Wealth Management sold 1,378 Nektar Therapeutics shares in Q2 2020, an estimated $369K.
  • AE Wealth Management first reported a position in Nektar Therapeutics in Q1 2020 and held it in 1 quarter.
  • AE Wealth Management's Nektar Therapeutics position peaked at $369K in Q1 2020.
  • 260 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2020.

Based on AE Wealth Management's 13F filing for Q2 2020, filed 5 Aug 2020.